By Jody Godoy PHILADELPHIA, March 17 (Reuters) - The U.S. Federal Trade Commission is on the lookout for anticompetitive practices in the pharmaceutical industry with a number of blockbuster drugs ...

Each year, companies invest significant financial resources building and maintaining patent portfolios. But instead of ...

Exploring the modern in-house patent department. Major trends shaping patent strategy, including a shift to quality over ...

We examine Bristol Myers Squibb’s pipeline strategy and therapeutic priorities in 2026, as it faces a major patent cliff in ...

The official patents looks nearly identical to the Subaru Performance-B STI Concept from the 2025 Japan Mobility Show ...

Incyte (INCY) looks undervalued vs the 2028 Jakafi patent cliff; see why non-Jakafi growth and pipeline optionality could ...

There are two new developments in Apple’s ongoing legal battle with health technology company Masimo over the Apple Watch’s ...

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a clinical-stage biotechnology company developing a pipeline of ...

Patent momentum expands Revive's bucillamine franchise across medical countermeasures, infectious diseases and ...

Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, ...

SEO Vendor’s newly granted patent, the Dynamic Content Generation Method (US 12,572,752 B2), enables AI agents to ...